Menu
  • About Currax
    • Our Purpose and Values
    • Leadership
    • Corporate & Business Development
    • Company Culture
  • Products
    • Branded Products
      • CONTRAVE®
      • ONZETRA® Xsail®
      • SILENOR®
      • TREXIMET®
    • Generic Products
    • Innovation
      • About Clinical Trials
      • Currax Pharmaceuticals Clinical Trials
      • Independent Research and Educational Grants
  • Responsibility
    • Currax Compliance Program and Annual Declaration
    • Currax Code of Business Conduct and Ethics
    • Currax Data Subject Request
    • State Disclosures
  • MEDIA
    • Press Releases
    • Video Library
    • Currax in the News
  • Careers
    • Benefits
    • EEO Statement
    • Search Jobs
    • Disclaimer/Warning
  • Contact Us
Currax Announces Outstanding 2024 Financial and Operational Performance
2024
January 10, 2025

Currax Announces Outstanding 2024 Financial and Operational Performance

Read more
January 3, 2025

Currax Introduces First CONTRAVE® TV Ad and “Cravings Don’t Own Me” Campaign, Highlighting Food Cravings Management and Weight Loss

Read more
September 24, 2024

Currax Pharmaceuticals Unveils New Disease Awareness Campaign to “Quiet the Food Noise,” a Key Barrier for Individuals Seeking Weight Loss

Read more
August 27, 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Read more
July 24, 2024

New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues

Read more
January 25, 2024

Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial

Read more

Currax Pharmaceuticals LLC. All rights reserved. This information is intended only for residents of the United States.

  • Terms of Use
  • Privacy Policy
  • Accessibility
  • Sitemap
  • Report An Adverse Event